File(s) under permanent embargo

Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation-positive advanced non-small cell lung cancer (Oscillate).

journal contribution
posted on 2023-03-17, 05:06 authored by Ann Livingstone
Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation-positive advanced non-small cell lung cancer (Oscillate).

History

Journal

Asia Pacific Journal of Clinical Oncology

ISSN

1743-7555

Publisher

Wiley

Usage metrics

Exports